OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

5.75USD-0.18 (-3.04%)Market Closed

Market Summary

USD5.75-0.18

Market Closed

-3.04%

OCUL Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

OCUL Stock Price

View Fullscreen

OCUL RSI Chart

OCUL Valuation

Market Cap

890.6M

Price/Earnings (Trailing)

-7.73

Price/Sales (Trailing)

14.88

Price/Free Cashflow

-10.22

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-28.25%

Return on Assets

-21.39%

Free Cashflow Yield

-9.78%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

59.8M

Rev. Growth (Yr)

10.47%

Rev. Growth (Qtr)

-0.19%

OCUL Earnings

Earnings (TTM)

-115.3M

Earnings Growth (Yr)

-113.89%

Earnings Growth (Qtr)

-121.93%

Breaking Down OCUL Revenue

Last 7 days

25.1%

Last 30 days

-29.7%

Last 90 days

18.6%

Trailing 12 Months

-7.3%

How does OCUL drawdown profile look like?

OCUL Financial Health

Current Ratio

21.39

Debt/Equity

0.02

Debt/Cashflow

-9.21

OCUL Investor Care

Shares Dilution (1Y)

99.79%

Diluted EPS (TTM)

-1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	59.8M	0	0	0
2023	51.7M	54.6M	57.7M	58.4M
2022	49.4M	49.9M	49.7M	51.5M
2021	22.1M	32.3M	38.6M	43.5M
2020	6.3M	7.3M	12.3M	17.4M
2019	2.1M	2.1M	2.5M	4.2M
2018	1.8M	2.0M	2.0M	2.0M
2017	1.9M	1.9M	1.9M	1.9M
2016	1.8M	1.8M	1.8M	1.9M
2015	1.2M	1.5M	1.8M	1.8M
2014	200.5K	391.0K	581.5K	772.0K
2012	0	0	0	10.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ocular Therapeutix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	summer road llc	bought	7,000,000	7.52	930,851	-
Feb 22, 2024	dugel pravin	acquired	-	-	854,979	executive chairman
Feb 22, 2024	nayak sanjay	acquired	-	-	80,300	chief strategy officer
Feb 05, 2024	mattessich antony c.	acquired	95,460	4.86	19,642	president and ceo
Feb 05, 2024	ozden rabia gurses	acquired	30,841	4.86	6,346	chief medical officer
Feb 05, 2024	notman donald	acquired	30,190	4.86	6,212	chief financial officer
Feb 05, 2024	strassburger philip c.	acquired	29,300	4.86	6,029	general counsel
Feb 05, 2024	white christopher g	acquired	28,722	4.86	5,910	chief business officer
Feb 03, 2024	notman donald	acquired	-	-	61,636	chief financial officer
Feb 03, 2024	white christopher g	acquired	-	-	39,980	chief business officer

Which funds bought or sold OCUL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	81.63	1,299,100	1,779,200	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	47.49	282,000	422,000	-%
May 06, 2024	HighTower Advisors, LLC	added	10.1	91,000	163,000	-%
May 06, 2024	Quantbot Technologies LP	new	-	423,150	423,150	0.02%
May 06, 2024	SG Americas Securities, LLC	added	47.34	175,000	263,000	-%
May 03, 2024	ESSEX INVESTMENT MANAGEMENT CO LLC	added	1.57	1,771,560	3,423,420	0.68%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-88.36	-839,000	262,000	0.02%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	added	25.39	70,441	115,643	-%
May 03, 2024	SIGNATUREFD, LLC	new	-	692	692	-%
May 03, 2024	TRUST CO OF VERMONT	unchanged	-	27,840	54,600	-%

Are Funds Buying or Selling OCUL?

Are funds buying OCUL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCUL

No. of Funds

Unveiling Ocular Therapeutix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 27, 2024	summer road llc	9.4%	14,360,633	SC 13D/A
Feb 14, 2024	opaleye management inc.	5.51%	6,070,000	SC 13G/A
Feb 13, 2024	vanguard group inc	4.46%	5,118,102	SC 13G/A
Jan 31, 2024	blackrock inc.	5.2%	5,761,533	SC 13G/A
Dec 28, 2023	venrock healthcare capital partners iii, l.p.	6.8%	7,775,760	SC 13G
Dec 22, 2023	deep track capital, lp	8.38%	9,230,769	SC 13G
Dec 18, 2023	summer road llc	11.6%	13,429,782	SC 13D/A
Feb 13, 2023	opaleye management inc.	7.89%	6,075,000	SC 13G/A
Feb 09, 2023	vanguard group inc	5.16%	3,976,853	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	4,952,737	SC 13G/A

Recent SEC filings of Ocular Therapeutix Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 07, 2024	DEFA14A	DEFA14A
May 07, 2024	S-8	Employee Benefits Plan
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 19, 2024	PRE 14A	PRE 14A
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report
Mar 25, 2024	S-3ASR	S-3ASR

Peers (Alternatives to Ocular Therapeutix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	17.66%	-8.12%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.45%	-26.53%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-4.99%	-13.89%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-1.56%	-17.34%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.34%	-51.87%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	6.53%	-0.98%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-0.20%	-12.84%	24.28	4.35	85.90%	-14.05%
NVAX	625.6M	983.7M	4.30%	-38.12%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	-0.70%	291.81%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-5.85%	11.55%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-3.32%	88.89%	-0.24	2.14	-13.45%	66.37%

Ocular Therapeutix Inc News

Latest updates

Ocular Therapeutix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.2%	14,774	14,802	15,081	15,186	13,374	14,076	11,965	12,266	13,187	12,309	12,153	11,718	7,342	7,349	5,876	1,569	2,609	2,256	829	650	492
Costs and Expenses	33.1%	46,391	34,851	34,295	35,756	35,923	33,437	33,509	32,182	31,020	30,358	31,682	31,949	27,570	21,692	19,882	19,453	19,223	23,657	23,973	22,249	20,150
S&GA Expenses	10.1%	10,183	9,246	9,315	11,153	10,835	10,533	10,186	10,140	9,063	9,137	9,576	8,391	8,086	6,811	6,520	6,153	7,130	7,142	6,777	7,225	3,347
R&D Expenses	28.0%	20,735	16,195	15,019	15,094	14,747	13,543	13,719	13,100	13,100	12,578	12,719	13,859	10,927	7,624	6,951	8,021	6,098	10,125	10,235	9,414	11,317
Interest Expenses	-2.4%	4,051	4,152	3,426	1,991	1,768	1,847	1,797	1,696	1,683	1,680	1,658	1,655	1,679	1,726	1,715	1,694	1,633	1,805	1,651	1,627	1,018
Net Income	-121.9%	-64,848	-29,220	-516	-20,682	-30,318	-15,542	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124
Net Income Margin	-39.4%	-1.93*	-1.38*	-1.16*	-1.66*	-1.72*	-1.38*	-1.19*	-0.65*	-0.45*	-0.15*	-2.29*	-3.19*	-	-	-	-	-	-	-	-	-
Free Cashflow	-49.0%	-34,142	-22,913	-7,991	-22,065	-23,352	-19,108	-13,963	-11,371	-18,876	-15,784	-13,258	-20,185	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	113.8%	539	252	162	123	129	149	159	173	188	205	218	231	243	262	98.00	107	73.00	79.00	89.00	90.00	101
Current Assets	123.8%	520	232	141	101	107	130	146	160	175	191	204	217	228	246	82.00	90.00	55.00	60.00	70.00	65.00	79.00
Cash Equivalents	147.5%	485	196	111	67.00	79.00	102	121	135	145	164	179	192	209	230	71.00	84.00	48.00	56.00	65.00	62.00	76.00
Inventory	11.7%	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Net PPE	-2.5%	11.00	12.00	12.00	13.00	12.00	10.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	8.00	9.00	9.00	10.00	10.00	11.00	11.00
Liabilities	-18.6%	131	161	155	119	119	114	112	107	108	117	130	150	160	186	102	102	84.00	82.00	77.00	81.00	76.00
Current Liabilities	-30.4%	24.00	35.00	35.00	32.00	30.00	31.00	29.00	26.00	24.00	26.00	25.00	22.00	27.00	27.00	23.00	14.00	11.00	12.00	11.00	10.00	9.00
Long Term Debt	-100.0%	-	9.00	9.00	30.00	29.00	29.00	28.00	28.00	27.00	26.00	26.00	25.00	25.00	24.00	24.00	26.00	25.00	24.00	23.00	24.00	23.00
LT Debt, Non Current	-100.0%	-	9.00	9.00	30.00	29.00	29.00	28.00	28.00	27.00	26.00	26.00	25.00	25.00	24.00	24.00	26.00	25.00	24.00	23.00	24.00	23.00
Shareholder's Equity	347.7%	408	91.00	8.00	3.00	10.00	35.00	46.00	66.00	80.00	88.00	87.00	80.00	83.00	76.00	-	5.00	-	-	11.00	8.00	26.00
Retained Earnings	-9.3%	-762	-697	-668	-667	-647	-616	-601	-577	-558	-545	-541	-544	-536	-539	-453	-441	-405	-383	-357	-338	-314
Additional Paid-In Capital	48.4%	1,170	789	676	671	657	652	648	643	638	634	629	625	620	615	450	447	394	380	369	347	340
Shares Outstanding	34.6%	155	115	79.00	79.00	78.00	77.00	77.00	77.00	77.00	76.00	77.00	76.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	406	-	-	-	284	-	-	-	1,079	-	-	-	478	-	-	-	169	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-50.9%	-33,887	-22,454	-7,732	-20,075	-19,973	-16,958	-13,169	-10,876	-18,600	-15,153	-12,982	-20,056	-17,359	-6,246	-13,658	-14,796	-18,854	-19,467	-19,544	-19,181	-19,386
Share Based Compensation	84.3%	7,978	4,328	4,512	4,413	4,572	4,234	4,240	4,281	4,209	3,841	3,758	4,292	3,086	2,104	1,936	1,826	1,665	1,953	3,169	1,695	1,942
Cashflow From Investing	44.4%	-255	-459	-259	-1,990	-3,379	-2,150	-794	-495	-276	-631	-276	-129	-158	-253	-214	-125	-249	-601	-419	-493	-725
Cashflow From Financing	197.0%	321,223	108,170	51,935	9,645	78.00	458	374	493	129	667	679	2,667	-1,162	163,913	220	51,063	12,818	9,091	18,612	5,338	42,300

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OCUL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue, net	$ 14,774	$ 13,374
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Product revenue, net	Product revenue, net
Cost of product revenue	$ 1,326	$ 1,214
Research and development	20,735	14,747
Selling and marketing	10,183	10,835
General and administrative	14,147	9,127
Total costs and operating expenses	46,391	35,923
Loss from operations	(31,617)	(22,549)
Other income (expense):
Interest income	3,922	563
Interest expense	(4,051)	(1,768)
Change in fair value of derivative liabilities	(5,152)	(6,563)
Loss on extinguishment of debt	(27,950)
Other expense		(1)
Total other income (expense), net	(33,231)	(7,769)
Net loss	$ (64,848)	$ (30,318)
Net loss per share, basic (in dollars per share)	$ (0.49)	$ (0.39)
Weighted average common shares outstanding, basic (in shares)	132,021,945	77,386,287
Net loss per share, diluted (in dollars per share)	$ (0.49)	$ (0.39)
Weighted average common shares outstanding, diluted (in shares)	132,021,945	77,386,287
Product revenue, net
Revenue:
Total revenue, net	$ 14,715	$ 13,214
Collaboration revenue
Revenue:
Total revenue, net	$ 59	$ 160

OCUL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 482,888	$ 195,807
Accounts receivable, net	26,546	26,179
Inventory	2,574	2,305
Restricted cash	150	150
Prepaid expenses and other current assets	7,666	7,794
Total current assets	519,824	232,235
Property and equipment, net	11,450	11,739
Restricted cash	1,614	1,614
Operating lease assets	6,059	6,472
Total assets	538,947	252,060
Current liabilities:
Accounts payable	6,453	4,389
Accrued expenses and other current liabilities	16,040	28,666
Deferred revenue	263	255
Operating lease liabilities	1,542	1,586
Total current liabilities	24,298	34,896
Other liabilities:
Operating lease liabilities, net of current portion	6,407	6,878
Derivative liabilities	19,624	29,987
Deferred revenue, net of current portion	14,068	14,135
Notes payable, net	66,456	65,787
Other non-current liabilities	111	108
Convertible Notes, net		9,138
Total liabilities	130,964	160,929
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 154,704,086 and 114,963,193 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	15	12
Additional paid-in capital	1,170,394	788,697
Accumulated deficit	(762,426)	(697,578)
Total stockholders' equity	407,983	91,131
Total liabilities and stockholders' equity	$ 538,947	$ 252,060

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

CEO	Mr. Antony Mattessich
WEBSITE	ocutx.com
INDUSTRY	Biotechnology
EMPLOYEES	274

Ocular Therapeutix Inc Frequently Asked Questions

What is the ticker symbol for Ocular Therapeutix Inc? What does OCUL stand for in stocks?

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocular Therapeutix Inc (OCUL)?

As of Tue May 07 2024, market cap of Ocular Therapeutix Inc is 918.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers. The fair value of Ocular Therapeutix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocular Therapeutix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocular Therapeutix Inc a good stock to buy?

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

What is Ocular Therapeutix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, OCUL's PE ratio (Price to Earnings) is -7.97 and Price to Sales (PS) ratio is 15.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.